GE Healthcare‘s (NYSE:GE) newly launched blood collection business Drawbridge Health said today it inked a strategic collaboration deal with Thorne Research to develop solutions for improving blood collection for health and wellness customers.
Through the deal, Thorne Research and subsidiary WellnessFX will gain access to Drawbridge Health’s proprietary blood draw integration, collection and sample stabilization single-device technology, the companies said.
“We are extremely excited about bringing this game-changing blood collection technology to our customers. The blood draw experience has long been the Achilles’ heel in the health and wellness market and we believe the Drawbridge solution has the potential to both improve the customer experience and provide health insights to more patients than ever before,” Thorne Research CEO Paul Jacobson said in a press release.
Drawbridge Health said its all-in-one blood sampling solution is currently under development, and that it intends to seek FDA clearance for the system some time in the future.
Thorne Research will gain exclusive rights to distribute future Drawbridge Health products within the US health and wellness industry, the companies said, in exchange for a multi-million dollar investment into Drawbridge. Thorne Research CEO Jacobson will also join Drawbridge’s board of directors as part of the deal.
“Our strategic collaboration with Thorne brings tremendous value and validation to the Drawbridge platform. Partnering with a proven leader in the health and wellness industry opens the door to significant opportunities within this important and rapidly growing market segment. We certainly welcome the addition of Paul Jacobson to our board,” Drawbridge Health CEO Lee McCracken said in a prepared statement.
Late last month, GE Healthcare announced the launch of Drawbridge Health.